Do not follow the first-order elimination (Clearance and
half-life are not useful).
Undergo Michaelis-Menten (nonlinear) kinetics (using parameters
Vmax, Km, Vd.)
When drug metabolism by liver enzymes is saturated, a dose
increase can cause the plasma concentration to increase disproportionately
(this can happen at therapeutic concentrations.)
Clearance is not constant, so it is not helpful in estimating
the time to reach steady state (Vmax and Km are used instead.)
90% protein bound (low albumin level increases the fraction
of free/active phenytoin.)
Vmax = 7mg/kg/day (Maximum rate of drug metabolism)
Km = 4mg/L (Michaelis-Menten constant)
Phenytoin is available in two different forms: phenytoin
acid (chewable tablets and suspension) and phenytoin sodium (capsules and
injectables). Phenytoin sodium is 92% phenytoin acid, so make dose adjustment
accordingly for their different bioavailability fractions (F=1 for phenytoin
acid and F=0.92 for phenytoin sodium).
PHENYTOIN PHARMACOKINETIC IS DIFICULT TO PREDICT
AND NOT AS ACCURATE AS DRUGS FOLLOWING FIRST-ORDER/LINEAR ELIMINATION. USE CLINICAL
JUDGMENT AND TREAT THE PATIENT, NOT THE NUMBERS.